January 6, 2009
AVEO Pharmaceuticals to Present at 27th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., January 6, 2009– AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 11:30 a.m. PST at the Westin St. Francis Hotel in San Francisco.
Mr. Ha-Ngoc is expected to discuss the company’s progress in 2008 and its Phase 2 clinical trial of its novel, triple VEGF receptor inhibitor, AV-951, which has completed enrollment of more than 270 patients with metastatic renal cell cancer, as well as outline AVEO’s goals and objectives for 2009.
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. The company’s lead product, AV-951, a potential best-in-class triple VEGF receptor inhibitor, is completing a Phase 2 clinical trial in more than 200 patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company’s website at www.aveopharma.com .